A. Guilhem

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients

J. Harlé, P. Duffau, T. Chinet, 2017, PloS one.

Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients

B. Bonnotte, A. Guilhem, S. Audia, 2017, PloS one.

Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia

S. Dupuis-Girod, A. Guilhem, S. Riviére, 2021, Orphanet Journal of Rare Diseases.

Seven cases of hereditary haemorrhagic telangiectasia-like hepatic vascular abnormalities associated with EPHB4 pathogenic variants

M. Vikkula, D. Lipsker, P. Magro, 2023, Journal of Medical Genetics.

Immunological abnormalities associated with hereditary haemorrhagic telangiectasia

C. Malcus, S. Dupuis-Girod, A. Guilhem, 2013, Journal of internal medicine.

Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL).

P. Duffau, S. Dupuis-Girod, A. Guilhem, 2023, Thrombosis research.